ANZTPA discussion paper released for comment
17 January, 2013 by AusBiotechA discussion paper concerning the harmonisation of Australian and New Zealand therapeutic goods regulation is now open for comment.
Phosphagenics plans pain patch trial in Feb
16 January, 2013 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) will launch a phase I trial of an oxymorphone pain patch in early February, less than six months after starting development on the product.
Bionomics boon from R&D Tax Incentive
15 January, 2013 by Dylan Bushell-EmblingBionomics (ASX:BNO) expects a larger-than-expected $4.2 million R&D tax incentive rebate for FY12, and will be now able to claim foreign expenditures under the program.
Australian bid wins international agricultural biotechnology conference
15 January, 2013 by AusBiotechAustralia has won the bid to host the 2015 Agricultural Biotechnology International Conference (ABIC), the world’s leading forum for the promotion of innovation in agricultural bioscience.
Bluechiip secures North America distribution deal
14 January, 2013 by Dylan Bushell-EmblingBluechiip (ASX:BCT) has signed a deal covering distribution of its temperature-resistant tracking chips in the North American sample storage market.
Patrys multiple myeloma trial progresses
14 January, 2013 by Dylan Bushell-EmblingPatrys (ASX:PAB) has started recruiting for a second group of three patients for its multiple myeloma trial, which will receive an escalated dose of antibody treatment PAB-SM6.
Productivity Commission releases draft report on compulsory licensing of patents
10 January, 2013 by AusBiotechAfter reviewing the compulsory licensing provisions in the patents system, the Productivity Commission has released a draft report, which is now open for comment until 8 February 2013.
Allied Healthcare explores new tissue engineering applications
10 January, 2013 by Tim DeanA study has shown Allied Healthcare’s (ASX:AHZ) tissue engineering technology has potential applications in hernia repair and pelvic floor reconstruction.
Sirtex yet to peak: Wong
09 January, 2013 by Tim DeanSirtex Medical (ASX:SRX) CEO Gilman Wong is confident the company will continue to grow at a similar rate to the last five years, with it announcing its 34th consecutive quarter of growth.
Invion repurposes blood pressure drug to target asthma
08 January, 2013 by Tim DeanNadolol is known for its role in treating blood pressure, but now Invion is conducting a phase II trial to assess its effects on asthma and chronic bronchitis.
Sirtex shines as biotech gears up for big year
08 January, 2013 by AusBiotechAs the year commences, Sirtex Medical is being hailed a stand-out performer for 2012 and some analysts are tipping the biotech sector to be a “hot space” in 2013.
Bioniche wraps up with Endo, forges path for Urocidin
08 January, 2013 by Tim DeanAfter reclaiming the rights to its bladder cancer treatment, Urocidin, Bioniche (ASX:BNC) is now considering seeking approval in the Canadian market.
Alchemia pulls plug on Audeo Oncology demerger
21 December, 2012 by Tim DeanLack of investor interest has caused Alchemia to abandon plans to spin off its cancer business into a separate company, Audeo Oncology.
Bionomics’ BNC210 anti-anxiety drug enters phase I
21 December, 2012 by Tim DeanIronwood Pharmaceuticals has commenced a phase I trial of Bionomics’ (ASX:BNO) anti-anxiety drug, BNC210.
AusBiotech wraps up a year in biotechnology
20 December, 2012 by AusBiotechThis year Australia’s biotechnology industry can celebrate Christmas knowing that despite the challenges in the sector, companies in Australia can be proud of the year’s achievements.
